Marshall Wace, LLP Silence Therapeutics PLC Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 228,418 shares of SLN stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
228,418
Previous 488,889
53.28%
Holding current value
$1.22 Million
Previous $3.36 Million
80.85%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SLN
# of Institutions
61Shares Held
22.7MCall Options Held
1.3KPut Options Held
2.6K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$16.2 Million2.06% of portfolio
-
Siren, L.L.C. New York, NY2.79MShares$14.9 Million0.45% of portfolio
-
Redmile Group, LLC San Francisco, CA2.21MShares$11.8 Million0.66% of portfolio
-
Morgan Stanley New York, NY2MShares$10.7 Million0.0% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.85MShares$9.88 Million0.44% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $192M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...